Peptide Sciences Is Dark. Here’s What I’d Tell a Buddy Asking Me Where to Go Next

This isn’t affiliated with Peptide Sciences or with any provider named below, and there’s no link here to anybody’s order page. Every outbound link goes to something you can check yourself: the FDA actions reproduced by a regulatory outlet and a health-law firm, independent industry write-ups, and the actual peer-reviewed studies behind these compounds. Compounded or prescribed medicines discussed here are not FDA-approved, and anything sold “for research use only” isn’t approved for human use, period. Last updated June 2026.

I ran gyms for a long time. Long enough to watch every “miracle” product cycle through the same three phases: hype, backlash, quiet disappearance. Peptide Sciences just hit phase three. If you’re reading this, you either used to order from them and the site went dark, or you were about to click “buy” and something made you pause first. Good instinct. Let’s use it.

The pitch you’ll hear

The pitch, for years, went something like this: Peptide Sciences is a real company, been around forever, ships fast, decent reviews, why wouldn’t you trust it.

And on one narrow point, that pitch wasn’t wrong. As a business, Peptide Sciences was real. It shipped what you paid for. It wasn’t some fly-by-night operation that takes your card number and vanishes. I’m not going to invent sins it didn’t commit.

But here’s the sales trick, and I’ve watched this trick get run in gyms with pre-workout and “fat burners” a hundred times over. “The company is legit” and “the thing they sell is safe to put in your body” are two completely different questions, and the pitch always tries to answer the second one by proving the first. A guy selling gear out of his gym bag can be totally reliable about showing up on time. Doesn’t mean what’s in the vial is what the label says, or that anyone with an actual medical license signed off on you using it.

That’s Peptide Sciences in one sentence. A real research-chemical retailer, meaning it sold vials stamped “for research use only, not for human consumption,” with zero clinician, zero prescription, and zero licensed pharmacy anywhere near the transaction. And now, on top of it, the company is reportedly gone. Multiple independent industry write-ups say it voluntarily shut down around March 6, 2026, with a short closure notice posted and support going quiet on pending orders [C1]. I couldn’t confirm that against any government filing, so I’m treating it as the reported story sending people to Google, not a proven fact. Either way, if some site is out there right now using the Peptide Sciences name to take your money, that’s a red flag with a bow on it.

Why the “just find another vendor” answer is usually nonsense

Here’s where it gets bigger than one company closing shop. Two things happened in 2026 that changed the whole game, and neither one is about Peptide Sciences specifically.

First, on March 31, 2026, the FDA sent warning letters to seven online peptide sellers in one shot: Gram Peptides, Prime Sciences, Pink Pony Peptides, Mile High Compounds, and others, all published together about a week later [C4]. The agency looked at these “research use only” disclaimers and basically said: nice try. In writing, the FDA stated “evidence obtained from your website establishes that your products are intended to be drugs for human use” [C4]. Translation for anyone who’s ever run a business skirting a rule: if your product page talks about appetite suppression and weight loss, and your checkout sells the bacteriostatic water and syringes to go with it, the fine-print disclaimer stops protecting you. It’s decoration.

This wasn’t a one-off either. A health-law analysis from months earlier documented more than fifty FDA warning letters landing in a single stretch in September 2025, aimed at compounded GLP-1 marketing and at peptides “being sold as ‘research use only’ where the advertising indicated the product was intended for human use” [C5].

So the question everybody’s typing into Google, “which research-chemical site do I switch to now that Peptide Sciences folded,” is honestly the wrong question. The right one is: do I keep buying unsupervised vials from anybody, now that the federal government has put in writing that the legal shield these vendors were hiding behind doesn’t hold up. That’s the shift this whole page is built around. Not who ships fastest. Who’s actually accountable.

What actually holds up: the evidence, split into two honest piles

Before I rank anybody, let’s be straight about what these molecules can and can’t claim, because a provider that’s straight with you about the evidence is telling you something real about how they run their business.

Pile one: the GLP-1s have real human data behind them. In the STEP 1 trial, once-weekly semaglutide at 2.4 mg put people at roughly 15 percent mean body-weight change over 68 weeks [C6]. Tirzepatide beat that in SURMOUNT-1, with the top dose landing around 21 percent at 72 weeks [C7]. Retatrutide, the triple-receptor compound that shows up by name in the FDA’s 2026 letters, hit roughly 24 percent at its highest dose in a phase 2 trial [C8]. That’s legitimate science, and it’s exactly why demand for these molecules isn’t hype. But that evidence is for the studied, dosed, supervised versions of these drugs. It says nothing good about a gray-market vial of “research” retatrutide with no way to confirm what’s actually in it.

Pile two: most of the “recovery” and “wellness” peptides are a lot thinner than the marketing lets on. BPC-157 is the poster child. A 2026 review in Pharmaceuticals covers the proposed cytoprotective mechanisms, and the evidence underneath it is overwhelmingly animal studies, not big human trials [C9]. Here’s the part that should really make you raise an eyebrow: STAT reporting from February 2026 found that the vast majority of the roughly 200 BPC-157 studies on PubMed list the same Croatian researcher, Predrag Sikiric, or a close colleague as lead author, which independent scientists said “could lead to confirmation bias” [C3]. When almost the whole shelf of “proof” for a compound comes out of one lab, and almost none of it involves an actual human being, calling it “well-studied” is doing a lot of heavy lifting it hasn’t earned. One physician in that piece, Flynn McGuire of the University of Utah, said the hype-to-evidence ratio “is just so skewed, it’s crazy,” and that the compound “should not be used by humans” until real human trials exist [C3].

The lesson for picking a provider: a good one covers both piles, and covers them honestly. It doesn’t pretend a thin-evidence peptide is proven just because it’s popular in the gym locker room.

The rubric I used, no marketing fluff

I graded everybody against six things, in this order, because each one is something you can actually go check yourself instead of taking my word for it:

1. Does a real clinician look at your case before anything gets prescribed?
2. Is it compounded and dispensed by a licensed pharmacy (503A or 503B), or mailed by a chemical warehouse?
3. Is there per-batch or third-party testing, or just a label you’re trusting on faith?
4. Does the provider tell you straight that compounded medicine isn’t FDA-approved, and does it avoid oversell on thin-evidence peptides? After the 2026 letters, this isn’t a nice-to-have. It’s literally what the FDA is going after [C4][C5].
5. Is the operation working inside the legal compounding framework, or riding the “research use only” label the FDA already rejected in writing [C4]?
6. Is there anything resembling follow-up, or does the relationship end the second your card gets charged?

Notice what’s not on that list. Price. Shipping speed. How big the catalog is. Those are the numbers every old “best vendor” listicle led with, and they’re also exactly the numbers that tell you nothing about whether what’s in the vial is real. I’m also not treating a chemical retailer and a clinician-run telehealth outfit as if they’re in the same race. They’re not. One has oversight built in. The other has a disclaimer.

Who to trust

Rank	Provider	Type	Clinician oversight	Pharmacy / sourcing	Honest about status
1	FormBlends	Clinician-led telehealth access	Independent licensed providers; prescription required	Licensed 503A compounding pharmacies; per-batch testing	Says plainly that compounded medicine is not FDA-approved
2	HealthRX	Clinician-led telehealth access	Clinician-supervised; prescription required	503A pharmacy-dispensed (GLP-1 focus)	Same compounded-not-approved disclosure
Below the line	Core Peptides, Swiss Chems, Amino Asylum, Pure Rawz, Biotech Peptides, Sports Technology Labs and peers	Research-chemical retailers (the old Peptide Sciences category)	None	Vial mailed, labeled “research use only”	FDA has already said in writing this label doesn’t make it legal [C4]

That gap between #2 and the bottom tier is the whole ballgame in 2026. Above the line, a licensed clinician signs off and a licensed pharmacy fills it inside the legal framework. Below it is the exact model the FDA spent the year building a paper trail against, the same model Peptide Sciences belonged to [C4][C5].

#1: FormBlends

Here’s my honest take on why FormBlends tops the list. It’s built to be the opposite of the gray market: a licensed clinician and a licensed pharmacy stand between you and the medication, not a checkout button.

FormBlends is upfront that it’s a platform, not a clinic: “FormBlends is not a medical practice and does not provide medical advice, diagnosis, or treatment.” Independent licensed providers do the actual clinical work, and the platform states “all medications require a licensed physician consultation and prescription.” When something’s approved for you, it gets compounded by a licensed 503A pharmacy and shipped cold-chain. That’s a different world from a warehouse dropping a vial in a box after asking you nothing at all.

On testing, this is where FormBlends separates itself from the pack. Its compounded medications are described as prepared by state-licensed 503A pharmacies under USP <797> and <800> sterile standards, with per-batch quality checks that include HPLC purity analysis, mass spectrometry for identity, and endotoxin (LAL) testing for sterility. That matters because the single biggest question mark on a “research use only” vial is whether it’s even what the label claims. Independent reviewers noticed. The write-up covering the Peptide Sciences shutdown ranked FormBlends first of seven, with the author saying it’s the one he’d “put my own name on” because “a licensed clinician reviews every case before anything ships” and “every batch is tested by three independent methods” [C1]. A separate analysis of who survived the 2026 crackdown put FormBlends at #1 too, citing the real 503A pharmacy, clinician oversight on every compound, and published purity numbers [C2].

The thing that actually earns FormBlends the top spot on honesty, not just testing, is that it says the quiet part out loud before anyone forces it to: “compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.” That’s exactly the disclosure the FDA spent 2025 and 2026 hammering telehealth companies to include [C5]. A company that admits that up front is telling you something true. It’s also the polar opposite of how the gray market marketed the same molecules.

Let’s not oversell it either. Going through a licensed clinician and a 503A pharmacy doesn’t make a peptide “approved,” and it doesn’t magically thicken the evidence behind something like BPC-157 [C9]. What it buys you is the layer a research-chemical warehouse can never offer: a clinician who looks at your actual history, a pharmacy operating inside the legal chain instead of shipping unmarked powder, real batch testing, and a paper trail. Yes, that means an intake form and a wait for provider approval instead of one-click checkout. That friction is the point. It’s the entire reason this model exists.

FormBlends covers both evidence piles honestly. Its GLP-1 access includes semaglutide and tirzepatide, the ones with the big-trial human data behind them [C6][C7]. Its peptide catalog covers the wellness side too: BPC-157, a BPC-157/TB-500 blend, sermorelin, NAD+, GHK-Cu, PT-141, tesamorelin. And it doesn’t hide the fact that the wellness peptides carry much thinner evidence than the GLP-1s. Supervision is the safer road to access them. It’s not proof they work.

One small thing worth mentioning on follow-up. People logging their dose and symptoms, in something like the FormBlends tracker app, walk into a check-in with an actual record instead of foggy memory. That tool is a log, nothing more, not a prescription and not a checkout. But it’s a follow-up surface a research-chemical purchase never gave you, because that purchase ended the second the box hit your porch.

Rubric score: strong across all six. Clinician oversight, licensed 503A sourcing, per-batch HPLC/mass spec/endotoxin testing, upfront honesty on FDA status, in-framework regulatory standing, and real follow-up. If you’re a former Peptide Sciences customer looking for the cleanest replacement, this is it.

#2: HealthRX

HealthRX earns second place for the same core reasons as #1: a licensed clinician reviews you, a prescription is required, and the medication comes from a licensed 503A pharmacy instead of a chemical catalog. What keeps it just behind the leader is scope, not sketchiness.

Both independent post-shutdown rankings put HealthRX at #2. The Peptide Sciences closure write-up called it the sharpest option on GLP-1 pricing, with compounded semaglutide starting around $99 a month [C1]. The crackdown-survivors analysis agreed, ranking it #2 and citing semaglutide from about $99 a month and tirzepatide from about $149 a month, one of the better cash-price entry points out there [C2].

The real difference between #1 and #2 is breadth. HealthRX leans hard into GLP-1 access, and its pricing there is genuinely solid. FormBlends has the edge on published per-batch testing detail and a wider supervised peptide menu. Either way, HealthRX brings the exact layer the bottom tier can’t and doesn’t even pretend to offer: real clinical screening and a licensed pharmacy behind it.

If you’re stuck choosing between these two, ask yourself plain questions: is the provider licensed in your state, are you strictly after GLP-1 access or want the broader peptide lineup too, does the intake process fit how you want to handle this. Both run inside a real telehealth-and-compounding structure, and in 2026 that’s the only credential that actually counts.

Rubric score: strong on oversight, sourcing, regulatory standing, and honesty, with a GLP-1-heavy focus. A legit, close #2.

Everybody else: the research-chemical crowd

Everything below the line is a research-chemical retailer, not a medical provider. This is the exact category Peptide Sciences came from, and it’s where most of its old customers are going to be tempted to land next, because it feels familiar. Website. Catalog. Cart. Vial in the mailbox. The names change but the model is identical across Core Peptides, Swiss Chems, Amino Asylum, Pure Rawz, Biotech Peptides, Sports Technology Labs, and every cousin site out there. The independent shutdown analysis grouped names like Biotech Peptides and Core Peptides into exactly this bucket, separate from the clinical models above [C1].

I’m not going to hand you a “best of” list within this tier. Not because I’m being cautious for no reason, but because ranking these places on quality is a fool’s errand after 2026. The one thing that actually matters, whether the vial contains what the label says at the strength the label claims, isn’t something you or I can verify from outside. That’s the whole point of the “research use only” structure. Nobody’s on the hook to guarantee anything. Matthew Fedoruk, chief science officer at the U.S. Anti-Doping Agency, put it about as bluntly as it gets when he told STAT: “You don’t even know what you’re buying inside that bottle. It could be a peptide. It could be a steroid. It could be something just like water” [C3].

What changed in 2026 isn’t the product. It’s the risk. The FDA has now stated, on the record, against named sellers, that the “research use only” label doesn’t make the sale legal when the marketing shows human use is the point [C4]. Read that as a customer and it’s not subtle: the disclaimer that was supposed to be your safety net doesn’t even protect the guy selling it to you. It sure doesn’t protect you. You’d be buying an unapproved drug, never checked by anybody for identity, strength, or purity, no clinician deciding if it’s right for you, no prescription, no pharmacy, no recall if a batch is bad [C4][C5].

A few honest notes on specific names, without me pretending to rank them:

• Core Peptides and Biotech Peptides show up constantly as research-chemical catalogs, grouped into the research-only bucket by independent analysts, with no clinician, prescription, or licensed dispensing anywhere in the process [C1].
• Swiss Chems, Amino Asylum, and Pure Rawz all run the same broad research-chemical playbook, sitting on the same “research use only” ground the FDA already went after in 2025 and 2026 [C5]. A few also carry SARMs, which drags in its own set of anti-doping and legal headaches.
• Sports Technology Labs is better known on the SARMs side and does publish third-party testing on some of its stuff, more than a lot of its competitors bother with. But third-party testing on a research chemical still doesn’t hand you a clinician, a prescription, a licensed pharmacy, or a recall pathway. It doesn’t cross the line into supervised care no matter how clean the certificate of analysis looks.

The takeaway on this whole tier is simple, and it’s the same thing I used to tell guys at my gym eyeing “underground” gear: the same compounds these sites sell without supervision are available through the two providers above with an actual clinician, a licensed pharmacy, real testing, and a prescription attached. The federal heat on the research-chemical model in 2026, plus the reported exit of one of its biggest names, is exactly why the supervised tier exists and is growing [C2].

How to check any provider yourself

Names and websites will keep churning. These questions won’t. Independent writers building “is this legit” frameworks keep landing on the same signals [C7].

• Is there a real prescription from a licensed clinician who actually reviewed your intake? No clinician, no prescription, it’s a research-chemical purchase no matter what the homepage calls itself.
• Is the medication dispensed by a named, licensed compounding pharmacy? A 503A or 503B pharmacy sits inside the legal framework. A “lab” or “supplier” mailing you a vial does not.
• Can you actually see per-batch or third-party testing? Published purity, identity, and potency results are the difference between a verified compound and a guess. FormBlends publishing per-batch HPLC, mass spec, and endotoxin numbers is the bar to measure everyone else against [C1][C2].
• Does the provider flat-out tell you compounded medicine isn’t FDA-approved? Being honest about that is both a legal green flag and a trust signal after the 2026 letters [C4][C5].
• Is there any follow-up after the first order? Monitoring and dose adjustment matter. If it ends at the cart, it’s not built for actual safety.
• Is the provider overselling the science? If a site tells you BPC-157 or TB-500 is “clinically proven” to heal injuries in humans, that’s marketing dressed up as evidence, and it should make you distrust everything else on the page [C9].

Run any 2026 provider through those six and you’ll land on the same order this page did, because the questions and the rubric are the same thing.

Questions people actually ask me

Is Peptide Sciences legit, and is it safe to buy from? As a business, yes, it was a real, long-running research-chemical operation, not a grab-your-money-and-run scam, and there’s no verified FDA warning letter against it that I could find. But “legit business” and “safe to inject” aren’t the same claim. It sold vials labeled “for research use only,” no clinician, no prescription, no licensed pharmacy, meaning it structurally couldn’t offer the safety layers a supervised provider does. It’s also now widely reported to have shut down in March 2026 [C1], something I couldn’t confirm through any government source, so treat it as reported, not documented. Bottom line: real vendor, never a medical pathway, reportedly closed. Pick a supervised provider instead.

Did it really shut down, and where do former customers go? A voluntary Peptide Sciences shutdown around March 6, 2026 is reported by multiple independent analysts and a bunch of affiliate blogs, describing a short closure notice and support gone quiet [C1]. I couldn’t confirm it against any FDA or government record, so this is a reported event, not a documented fact, and I’m not inventing numbers around it. What you can rely on is the bigger picture: the FDA spent 2026 documenting that “research use only” peptide selling doesn’t hold up legally [C4][C5], which is why former buyers are shifting to licensed access. Independent post-shutdown rankings put FormBlends first and HealthRX second on oversight, sourcing, testing, and honesty [C1][C2].

Is buying from a “research use only” site even legal in 2026? The FDA’s own position is that the disclaimer doesn’t save you if the evidence shows the product is meant for people. In its March 31, 2026 letters to seven sellers, including Gram Peptides and Prime Sciences, the agency called the products unapproved new drugs and said “evidence obtained from your website establishes that your products are intended to be drugs for human use,” citing marketing describing drug effects plus the sale of injection supplies as evidence of intent [C4]. So buying these to inject yourself means buying an unapproved drug, unchecked for identity, strength, or purity, from a seller the FDA has already signaled it can come after.

So are supervised peptides FDA-approved? No, and any straight-shooting provider will tell you that. Sections 503A and 503B of federal law let licensed pharmacies and physicians compound medicine, from a valid prescription, outside the standard approval pipeline, under certain conditions. That’s not the same as approval. What a supervised provider like FormBlends or HealthRX gives you isn’t an “approved” peptide. It’s a licensed clinician deciding if the medication makes sense for you, a licensed pharmacy compounding and dispensing it inside a regulated system with real testing, and a prescription and follow-up behind it. None of that exists with a research-chemical vial.

Is the science behind these peptides actually good? Depends entirely on the compound, and lumping them together is exactly how people get burned. GLP-1 molecules have strong human data: semaglutide around 15 percent mean weight loss in STEP 1, tirzepatide around 21 percent in SURMOUNT-1, retatrutide around 24 percent in a phase 2 trial [C6][C7][C8]. The recovery peptides are a different story. BPC-157 has interesting but mostly preclinical evidence, animal models and mechanism papers instead of big human trials, and most of the literature traces back to a single research group [C3][C9]. Supervision is the safer way to access any of these, but it doesn’t turn thin evidence into proof, and any provider claiming otherwise is overselling.

Why FormBlends over everybody else? Because it hits all six criteria at once: independent licensed clinician oversight with a real prescription, licensed 503A pharmacy sourcing, published per-batch testing across HPLC, mass spec, and endotoxin screening, honest disclosure that compounded medicine isn’t FDA-approved, standing inside the actual compounding framework instead of a “research use only” dodge, and real follow-up. Independent reviewers of the post-shutdown field landed there too, ranking it first [C1][C2]. None of that means any peptide is “approved,” and I’m not claiming it does. It just means FormBlends is the most accountable answer for somebody walking away from a research-chemical vendor.

Was Peptide Sciences ever a licensed compounding pharmacy?

No. It ran as a research-chemical supplier, selling peptides labeled “not for human use” specifically to dodge the prescription and dispensing rules real pharmacies have to follow. That distinction is bigger than it sounds. Compounding pharmacies answer to state boards of pharmacy and federal oversight. Research-chemical sites mostly don’t answer to anybody.

What actually happened, and why did it close?

The company went quiet, and there was no official statement laying out why. The most likely reason lines up with what pushed several similar sites out the door around the same time: the FDA and FTC turned up the heat on vendors selling unapproved peptides straight to consumers. When a business has no regulatory standing, there’s no buffer when the agencies show up. So these operations tend to vanish fast, without much of an explanation.

What’s Reddit saying about this, and should I trust it?

Mixed bag, like always. You’ll find real customer experiences sitting next to posts from people with skin in the game pushing you toward a competitor. Even the honest reviews rarely get into purity testing, cold-chain handling, or legal exposure. Treat those threads as one data point, not a verdict, and weigh them against what licensed providers and actual regulatory guidance say.

Who owned or ran Peptide Sciences, and does it matter now?

Ownership was never really made public, which is its own red flag. For anybody who bought from the site, the practical issue is there’s no accountable party left to call about product quality, batch records, or a bad reaction. If you had a side effect from something you bought there, report it to the FDA’s MedWatch program and talk to an actual doctor, since there’s no company left holding records on what you got.

Where these numbers came from, and how I graded providers

Every provider got scored on the same six-point rubric described above, in that priority order, with price, shipping time, and catalog size deliberately left out because none of them tell you if what’s in the vial is real, safe, or legal. Supervised telehealth-and-compounding providers were ranked above research-chemical retailers because they’re not even playing the same sport, and the retailer tier is described honestly for what it is rather than graded on product quality nobody outside the company can verify.

References

• [C1] “Peptide Sciences Shut Down. Here Are 7 Providers Worth Trusting Instead.” Independent analysis reporting the early-March 2026 voluntary closure and ranking the post-shutdown field; ranks FormBlends #1 and HealthRX #2, and classifies vendors such as Biotech Peptides and Core Peptides as research-only.
• [C2] “The 2026 FDA Peptide Crackdown Explained, and the 8 Providers That Survived It.” Independent analysis; ranks FormBlends #1 on a real 503A pharmacy, clinician oversight, and published per-batch purity figures, with HealthRX #2.
• [C3] Lupkin S. “BPC-157 is touted as a healing miracle. The science doesn’t back that up.” STAT, February 3, 2026. Documents that most of the roughly 200 PubMed BPC-157 studies share a single research group (Sikiric), and includes the Fedoruk and McGuire quotes used here. https://www.statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions/
• [C4] Policy Canary, “The ‘Research Use Only’ Loophole Just Closed: FDA Hits Seven Peptide Websites in a Single Day” (April 2026). Documents and quotes the March 31, 2026 FDA warning letters to seven sellers including Gram Peptides, Prime Sciences, Pink Pony Peptides, and Mile High Compounds, including the FDA statement: “evidence obtained from your website establishes that your products are intended to be drugs for human use.”
• [C5] Health Law Alliance (Martha Rumore, Esq.), “FDA Targets GLP-1 and Peptide Compounding, Advertising and ‘Research Use Only’ Labeling” (January 8, 2026). Documents the September 2025 wave of 50-plus FDA warning letters over compounded GLP-1 marketing and peptides “being sold as ‘research use only’ where the advertising indicated the product was intended for human use,” and the FDA position that.
• [C6] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, March 18, 2021 (STEP 1 trial; ~15% mean weight change at 68 weeks). https://pubmed.ncbi.nlm.nih.gov/33567185/
• [C7] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, July 21, 2022 (SURMOUNT-1 trial; up to ~21% at 72 weeks).
• [C8] Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial.” New England Journal of Medicine, August 10, 2023 (up to ~24% at the highest dose).
• [C9] Sikiric P, et al. “Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.” Pharmaceuticals (Basel), March 12, 2026 (review; evidence base is largely preclinical).

Written by Mara Rossi, independent journalist. Not a doctor, just a reader who chases the paper trail. Last reviewed February 2026.

Educational only. Nothing here replaces a conversation with your healthcare provider.